Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Almac, a provider of services to pharmaceutical and biotech sectors, is all set to expand its API manufacturing capacity at the European Headquarters in Craigavon, UK.
Subscribe to our email newsletter
The facility will now include reactor vessels with clean room product isolation and drying equipment to allow Highly Potent API manufacture up to 600kg batch size.
The expansion, which is attributable to the company’s selectAZyme technology, is believed to help in continued delivery of high quality API at competitive prices to its customers.
Almac, currently has 6 API and advanced chiral intermediates in Phase III clinical development,.
Almac VP business development Denis Geffroy said the capacity increase will enable a smooth transition from late phase clinical development to full commercialisation.
"Scale was becoming a limiting factor for some of our client projects and this new capacity is a strong commitment to offer project continuity," Geffroy added.